Drug Profile
Donanemab - Eli Lilly and Company
Alternative Names: LY 3002813; LY3002813-IV; LY3002813-SC; N3pG-AB-monoclonal-antibody-Eli-Lilly; N3pG-amyloid-beta Monoclonal Antibody; N3pG-Aβ mAbLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Alzheimer's disease
Most Recent Events
- 19 Sep 2023 Eli Lilly and company completes the phase III TRAILBLAZER-ALZ 4 trial for Alzheimer's disease in USA (IV) (NCT05108922)
- 08 Aug 2023 Preregistration for Alzheimer's disease in Japan (IV), prior to August 2023 (Eli Lilly and Company presentation, August 2023)
- 08 Aug 2023 Preregistration for Alzheimer's disease in European Union (IV)